This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hatta, M.
Right arrow Articles by Kawaoka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hatta, M.
Right arrow Articles by Kawaoka, Y.

 Previous Article  |  Next Article 

Journal of Virology, May 2003, p. 6050-6054, Vol. 77, No. 10
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.10.6050-6054.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

The NB Protein of Influenza B Virus Is Not Necessary for Virus Replication In Vitro

Masato Hatta1 and Yoshihiro Kawaoka1,2,3*

Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Institute of Medical Science, University of Tokyo, Tokyo 108-8639 ,2 Core Research for Evaluational Science and Technology, Japan Science and Technology Corporation, Saitama 332-0012, Japan3

Received 19 November 2002/ Accepted 10 February 2003


arrow
ABSTRACT
 
The NB protein of influenza B virus is thought to function as an ion channel and therefore would be expected to have an essential function in viral replication. Because direct evidence for its absolute requirement in the viral life cycle is lacking, we generated NB knockout viruses by reverse genetics and tested their growth properties both in vitro and in vivo. Mutants not expressing NB replicated as efficiently as the wild-type virus in cell culture, whereas in mice they showed restricted growth compared with findings for the wild-type virus. Thus, the NB protein is not essential for influenza B virus replication in cell culture but promotes efficient growth in mice.


arrow
INTRODUCTION
 
The genome of Influenza B virus, a member of the family Orthomyxoviridae, consists of eight negative-strand RNA segments, which encode 11 proteins. Of these, nine are also found in influenza A virus: three RNA-dependent RNA polymerase subunits (PB1, PB2, and PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix protein (M1), and two nonstructural proteins (NS1 and NS2). Two proteins, NB and BM2, are unique to influenza B virus. NB is encoded by RNA segment 6, which also encodes NA, while BM2 is encoded by segment 7.

The NB protein of influenza B virus is a type III integral membrane protein, expressed abundantly on the surface of virus-infected cells (5, 30, 31), and is incorporated into virions (5, 7). This small protein (100 amino acids) possesses an 18-residue N-terminal ectodomain, a 22-residue transmembrane domain, and a 60-residue cytoplasmic tail (5, 42). From previous studies measuring membrane currents and by analogy with the M2 protein of influenza A virus (12, 13, 35), NB is thought to function as an ion channel protein. However, the electrophysiological measurements of the NB protein based on the lipid bilayer system are difficult to interrupt. That is, proteins and peptides containing hydrophobic domains, which are believed to lack ion channel activity in cells, can yield channel recordings in lipid bilayers (22, 39, 40). Moreover, in the studies of Fischer et al. (13) and Sunstrom et al. (35), amantadine was used to demonstrate the loss of channel activity by the NB protein, despite the inability of this drug to inhibit influenza B virus replication. Thus, the available evidence challenges the notion that the NB protein has ion channel activity.

Recently, members of our group and others (14, 16, 23) established a reverse genetics system for generating influenza A virus entirely from cloned cDNAs, based on the in vivo synthesis of viral RNA. This innovation led us to devise a similar system to determine the importance of the NB protein in the life cycle of influenza B virus (Hoffmann et al. [17] and Jackson et al. [20] reported a reverse-genetics strategy for influenza B virus while this report was being prepared). Here, we generated influenza B virus NB knockout viruses by reverse genetics and tested their growth characteristics and other properties both in cell culture and in mice.


arrow
MATERIALS AND METHODS
 
Cells, viruses, and antibodies. 293T human embryonic kidney cells and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum and in minimal essential medium containing 5% newborn calf serum, respectively. The 293T cell line is a derivative of the 293 line, into which the gene for the simian virus 40 T antigen was inserted (9). All cells were maintained at 37°C in 5% CO2. An anti-NB rabbit serum was generated against the synthesized peptide NKRDDISTPRAGVD (amino acid residues 70 to 83 of the NB protein) coupled to keyhole limpet hemocyanin.

Construction of plasmids. The cDNAs of B/Lee/40 virus were synthesized by reverse transcription of viral RNA with an oligonucleotide complementary to the conserved 3' end of the viral RNA. The cDNA was amplified by PCR with gene-specific oligonucleotide primers containing BsmBI sites, and PCR products were cloned into the pT7Blueblunt vector (Novagen, Madison, Wis.). After digestion with BsmBI, the fragment was cloned into the BsmBI sites of a plasmid vector, which contains the human RNA polymerase I promoter and the mouse RNA polymerase I terminator, separated by BsmBI sites. These plasmids for the expression of virion RNA are referred to as PolI constructs in this report. The cDNAs encoding the PB2, PB1, PA, and NP genes of B/Lee/40 virus were cloned into the eukaryotic expression vector pCAGGS/MCS (controlled by the chicken ß-actin promoter) (21, 24), resulting in pCABLeePB2, pCABLeePB1, pCABLeePA, and pCABLeeNP, which express the PB2, PB1, PA, and NP proteins, respectively.

The NB knockout mutants were constructed as follows. Mutated NA genes (see Fig. 1) were amplified by PCR from the PolI construct containing the B/Lee/40 NA gene and then digested with BsmBI. The sequences of the primers will be provided upon request. The BsmBI-digested fragment was cloned into the BsmBI sites of the PolI plasmid. The resulting constructs were designated pPolBLeeNBstop#1, pPolBLeeNBstop#2, and pPolBLeeNBstop#3. All of the constructs were sequenced to ensure that unwanted mutations were not present.



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 1. Schematic diagram of mutations introduced into the NA segment. Mutations are shown in bold (-, deletion; *, insertion). The numbers shown are nucleotide positions.

Plasmid-based reverse genetics. Transfectant viruses were generated as reported earlier (23). Briefly, 12 plasmids (eight PolI constructs for eight RNA segments and four protein-expression constructs for polymerase proteins and NP) were mixed with transfection reagent (Trans IT LT-1 [Panvera, Madison, Wis.]), incubated at room temperature for 10 min, and added to 106 293T cells cultured in Opti-MEM (Invitrogen) containing 0.3% bovine serum albumin. Forty-eight hours later, viruses in the supernatants were collected and amplified in MDCK cells for the production of stock viruses.

Indirect immunofluorescence assay. MDCK cells were infected with viruses at a multiplicity of infection (MOI) of 1 to 2 PFU per cell. After 8 h of infection, cells were fixed with 3% formaldehyde solution and permeated with 0.1% Triton X-100. Antigens were detected with rabbit anti-NB peptide rabbit serum as a primary antibody and fluorescein isothiocyanate-conjugated anti-rabbit immunoglobulin G as a secondary antibody.

Immunoprecipitation. Influenza B virus-infected MDCK cells (MOI, 5 PFU/cell) were labeled with a mixture of [35S]Met and [35S]Cys (50 µCi/ml each) (Tran35S-label; ICN Biochemicals) at 7 h postinfection for 2 h. The radiolabeled cells were lysed in RIPA buffer containing 10 mM Tris-HCl (pH 7.5)-100 mM NaCl-1 mM EDTA-0.5% Triton X-100 and then centrifuged. The anti-NB rabbit serum was added to the supernatant and incubated overnight at 4°C. Protein A-Sepharose beads were then added and incubated for 1 h at room temperature. The immune complexes were washed and separated on 4 to 20% gradient polyacrylamide gels (ISC BioExpress, Kaysville, Utah). The gels were dried and examined by autoradiography.

Replicative properties of transfectant viruses. MDCK cells were infected with viruses at an MOI of 0.001 PFU per cells, overlaid with MEM medium containing 0.5 µg of trypsin per ml, and incubated at 37°C. Supernatants were assayed at different times for infectious virus in plaque assays on MDCK cells.

Experimental infection. Five-week-old female BALB/c mice, anesthetized with methoxyflurane, were infected intranasally with 50 µl of virus. The dose lethal for 50% of mice (MLD50) was determined as previously described (15). The replicative capacity of virus was determined by intranasally infecting mice (1.0 x 104 PFU) and determining titers of virus in organs at 3 days postinfection, as described by Bilsel et al. (6).


arrow
RESULTS
 
Generation of B/Lee/40 virus by reverse genetics. As a first step in determining the role(s) of the NB protein in virus replication, we generated B/Lee/40 (B/Lee) virus entirely from cloned cDNA, using plasmid-based reverse genetics (23). The plasmids contained cDNAs encoding all eight segments of B/Lee virus, flanked by the human RNA polymerase I promoter and the mouse RNA polymerase I terminator. We then transfected 293T cells with four plasmids expressing the PA, PB1, PB2, and NP proteins of B/Lee virus and eight plasmids that directed the production of eight viral RNA segments of B/Lee virus. Forty-eight hours after transfection, the virus, designated B/LeeRG, was recovered from the supernatant of 293T cells (103.5 50% tissue culture infectious dose).

NB protein knockout viruses are viable. Using this reverse genetics system, we next attempted to generate mutant viruses that did not express the NB protein. We made three mutant PolI constructs, designated pPolBLeeNBstop#1, pPolBLeeNBstop#2, and pPolBLeeNBstop#3 (Fig. 1). In all mutant constructs, the initiation codon of the NB protein was converted from ATG to GCG (Met to Ala), and the codon at amino acid position 41 of the NB protein was changed from AAA to TAA (stop codon). pPolBLeeNBstop#2 has a single nucleotide deletion downstream of the mutated initiation codon, which was expected to alter the reading frame of the NB protein. pPolBLeeNBstop#3 has a nucleotide insertion downstream of the mutated initiation codon, which also was expected to alter the reading frame of the NB protein. At 48 h after transfection of 293T cells with each mutant NA PolI plasmid, together with seven other PolI plasmids and four protein expression plasmids, BLeeNBstop#1, BLeeNBstop#2, and BLeeNBstop#3 viruses were recovered from the supernatant (103.5 50% tissue culture infectious dose), indicating that all viruses lacking the NB protein were generated with an efficiency equivalent to that of the wild-type B/Lee virus. The transfectant viruses present in the supernatant were grown in MDCK cells and used as stock viruses. Sequencing of the NA gene of each stock virus confirmed the stability of the desired mutations and ruled out the introduction of additional mutations.

To confirm that the three mutant viruses did not express the NB protein, as intended, we performed indirect immunofluorescence assays and immunoprecipitation assays using virus-infected MDCK cells (Fig. 2A and B). None of the mutants was positive, in contrast to the B/LeeRG virus, which expressed NB. In immunoprecipitation studies, the NB protein was identified as an 18-kDa protein (high-mannose form) and as ~30- to 50-kDa proteins (heterogeneous form) in agreement with the previously reported results (42, 43). Several cells infected with BLeeNBstop#1 virus showed faint, diffuse cytoplasmic staining in the immunofluorescence assays, which might indicate the production of a short NB peptide produced by alternative initiation and readthrough of the stop codon introduced. Thus, all three mutant viruses were viable and did not express the full-length NB protein.




View larger version (64K):
[in this window]
[in a new window]
  		FIG. 2. Analysis of the expression of NB protein. (A) Detection of NB protein in infected MDCK cells by immunofluorescence assay. B/LeeRG, B/LeeRG-infected; WSN, A/WSN/33-infected; Control, uninfected; #1, #2, and #3, BLeeNBstop#1-, BLeeNBstop#2-, and BLeeNBstop#3-infected cells, respectively. (B) Detection of NB protein in virus-infected MDCK cells by immunoprecipitation assays. Radiolabeled NB proteins were immunoprecipitated with a rabbit anti-NB peptide serum and analyzed on 4 to 20%-gradient polyacrylamide gels as described in Materials and Methods. Lane #1, BLeeNBstop#1-infected; lane #2, BLeeNBstop#2-infected; lane #3, BLeeNBstop#3-infected; lane C, uninfected cell lysate. Molecular mass markers (kDa) are indicated.

Growth properties of NB knockout viruses in cell culture. MDCK cells were infected with B/LeeRG, BLeeNBstop#1, BLeeNBstop#2, or BLeeNBstop#3 viruses at an MOI of 0.001 PFU per cell and incubated at 37°C. The supernatants were collected at different times postinfection, and titers of virus were determined by plaque assays with MDCK cells. BLeeNBstop#1, BLeeNBstop#2, and BLeeNBstop#3 viruses showed growth kinetics similar to those of B/LeeRG, with virus titers reaching 107 PFU/ml at 36 h postinfection (Fig. 3). These results indicate that in cell culture, influenza B virus can undergo multiple cycles of replication and grow well without the NB protein.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 3. Growth curves for B/LeeRG and mutant viruses. MDCK cells were infected with virus (0.001 PFU) and incubated at 37°C. At the indicated times after infection, titers of virus were determined in the supernatant. The values are means (± standard deviation) of three determinations.

Replication of NB knockout viruses in mice. To determine the role of NB in influenza B virus replication in vivo, we first compared the MLD50 of the wild-type and mutant viruses (Table 1). The MLD50 values for NB knockout viruses were at least 1 log higher than the value for B/LeeRG. In tests of virus replication in the lungs and nasal turbinates of mice infected with 104 PFU of virus (Table 1), B/LeeRG grew well in both sites, while the growth of mutant viruses was restricted, as shown by titers of virus that were generally more than 1 log lower than the titer for mutant viruses. Thus, although not required for growth in cell culture, the NB protein appears important for efficient replication of influenza B virus in mice.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Role of NB in virus replication in micea


arrow
DISCUSSION
 
Here we demonstrate that the NB protein is not essential for replication of influenza B virus in cell culture but promotes efficient replication in vivo. In this regard, NB is similar to the M2 protein of A/WSN/33 influenza virus, although the requirement for NB during in vivo replication appears less stringent than that for the M2 protein. An A/WSN/33 mutant lacking the transmembrane and cytoplasmic domains of M2 was severely attenuated in mice (41), and a mutant of A/Udorn/72 (H3N2) lacking nucleotides encoding amino acid residues 29 to 31 of the M2 protein was attenuated even in cell culture (36). Although the ion channel activity of M2 is experimentally well established (10, 18, 27, 33, 34), such activity has not been unequivocally demonstrated for the NB protein. Thus, the limited dependency of influenza B virus on NB function may suggest either that the virus does not depend as much on ion channel activity as influenza A virus does or that NB has functions other than ion channel activity. Since NB is highly conserved among influenza B virus strains, such functions must be important for viral replication in a natural setting.

Current human vaccines are inactivated vaccines that reduce the severity of, but are limited in their ability to prevent, viral infection. Clinical trials of cold-adapted live attenuated vaccines have generated promising results with respect to both efficacy and safety (1, 2, 3, 4, 8, 19, 25, 32, 38, 44). However, a molecular basis for the attenuation of the master vaccine strain of influenza B viruses remains unknown. Thus, it is important to produce an influenza B virus with known attenuating mutations. It would be ideal to produce a master vaccine strain which contains attenuating mutations exclusively in genes other than the HA and NA genes, so that only the latter genes need replacement with those of a field strain for vaccine production. However, with the invention of reverse genetics, it is no longer difficult to modify even the HA and NA genes for vaccine production. Thus, the mutations to knockout NB expression may be included, in addition to other attenuating mutations, in vaccine strains, considering that no growth defect was detected with NB knockout viruses in cell culture.

Although the replicative abilities of NB knockout viruses were similar to each other in MDCK cells, they differed in mice. This difference in replicative ability among the mutants in mice may originate from different levels of NA expression. To knock out NB expression, the upstream sequence of the NA protein was modified. This might have altered NA protein expression levels, resulting in various extents of attenuation in vivo. Further experiments are in progress to clarify this point.

Thus far, five viral proteins have been reported to act as ion channels: the M2 protein of influenza A virus, the NB protein of influenza B virus, Vpu and Vpr of human immunodeficiency virus type 1 (HIV-1), and Kcv of chlorella virus (11, 26, 28, 29, 33, 34, 35). The Vpr and Kcv proteins have been demonstrated to play an important role in the viral life cycle. The Vpu gene of HIV-1 can be deleted without completely abrogating HIV-1 replication in vitro. In the present study, we show that the NB protein is not necessary for viral growth in cell culture but appears to be required for efficient influenza B virus replication in mice. The lack of an apparent growth defect of NB knockout viruses in cell culture suggests the difficulty of determining the true function of this protein. Since the effects of mutations in the M2 protein differ among viral strains (36, 37), it is possible that deletion of the NB protein may produce growth defects in some influenza B viruses but not in others. Hence, it will be important to determine the effects of NB deletion in influenza B virus strains other than B/Lee/40.


arrow
ACKNOWLEDGMENTS
 
We thank Krisna Wells, Martha McGregor, and Susan Kalis for excellent technical assistance and John Gilbert for editing the manuscript. We also thank A. Portela for providing us with the plasmids encoding the PA, PB1, PB2, or NP gene of B/Panama/45/90 virus, which were used for control experiments. Automated sequencing was performed at the University of Wisconsin—Madison, Biotechnology Center.

This work was supported by grants from the National Institutes of Health, NIAID, by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and Welfare, Japan, and by grants of Core Research for Evaluational Science and Technology (CREST) from Japan Science and Technology Corporation (JST), Japan.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin—Madison, Madison, WI 53706. Phone: (608) 265-4925. Fax: (608) 265-5622. E-mail: kawaokay{at}svm.vetmed.wisc.edu. Back


arrow
REFERENCES
 
    1
  1. Abbasi, S., W. Gruber, K. Edwards, L. Gubareva, R. G. Webster, and Y. Kawaoka. 1995. The HA1 of cold-adapted influenza B vaccine is not altered during replication in human vaccinees. Virus Res. 39:377-383.[CrossRef][Medline]
    2. 2
  2. Alexandrova, G. I., G. N. Budilovsky, T. A. Koval, F. I. Polezhaev, L. M. Garmashova, Y. Z. Ghendon, Y. R. Romanova, and A. A. Smorodintsev. 1986. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 4:114-118.[CrossRef][Medline]
    3. 3
  3. Anderson, E. L., F. K. Newman, H. F. Maassab, and R. B. Belshe. 1992. Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children. J. Clin. Microbiol. 30:2230-2234.[Abstract/Free Full Text]
    4. 4
  4. Belshe, R. B., P. M. Mendelman, J. Treanor, J. King, W. C. Gruber, P. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, D. Iacuzio, and M. Wolff. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338:1405-1412.[Abstract/Free Full Text]
    5. 5
  5. Betakova, T., M. V. Nermut, and A. J. Hay. 1996. The NB protein is an integral component of the membrane of influenza B virus. J. Gen. Virol. 77:2689-2694.[Abstract/Free Full Text]
    6. 6
  6. Bilsel, P., M. R. Castrucci, and Y. Kawaoka. 1993. Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions. J. Virol. 67:6762-6767.[Abstract/Free Full Text]
    7. 7
  7. Brassard, D. L., G. P. Leser, and R. A. Lamb. 1996. Influenza B virus NB glycoprotein is a component of the virion. Virology 220:350-360.[CrossRef][Medline]
    8. 8
  8. Cha, T. A., K. Kao, J. Zhao, P. E. Fast, P. M. Mendelman, and A. Arvin. 2000. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 38:839-845.[Abstract/Free Full Text]
    9. 9
  9. DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.[Abstract/Free Full Text]
    10. 10
  10. Duff, K. C., and R. H. Ashley. 1992. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 190:485-489.[CrossRef][Medline]
    11. 11
  11. Ewart, G. D., T. Sutherland, P. W. Gage, and G. B. Cox. 1996. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70:7108-7115.[Abstract/Free Full Text]
    12. 12
  12. Fischer, W. B., M. Pitkeathly, B. A. Wallace, L. R. Forrest, G. R. Smith, and M. S. Sansom. 2000. Transmembrane peptide NB of influenza B: a simulation, structure, and conductance study. Biochemistry 39:12708-12716.[CrossRef][Medline]
    13. 13
  13. Fischer, W. B., M. Pitkeathly, and M. S. Sansom. 2001. Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B. Eur. Biophys. J. 30:416-420.[CrossRef][Medline]
    14. 14
  14. Fodor, E., L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, and A. Garcia-Sastre. 1999. Rescue of influenza A virus from recombinant DNA. J. Virol. 73:9679-9682.[Abstract/Free Full Text]
    15. 15
  15. Gao, P., S. Watanabe, T. Ito, H. Goto, K. Wells, M. McGregor, A. J. Cooley, and Y. Kawaoka. 1999. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J. Virol. 73:3184-3189.[Abstract/Free Full Text]
    16. 16
  16. Hoffmann, E., and R. G. Webster. 2000. Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids. J. Gen. Virol. 81:2843-2847.[Abstract/Free Full Text]
    17. 17
  17. Hoffmann, E., K. Mahmood, C. F. Yang, R. G. Webster, H. B. Greenberg, and G. Kemble. 2002. Rescue of influenza B virus from eight plasmids. Proc. Natl. Acad. Sci. USA 99:11411-11416.[Abstract/Free Full Text]
    18. 18
  18. Holsinger, L. J., D. Nichani, L. H. Pinto, and R. A. Lamb. 1994. Influenza A virus M2 ion channel protein: a structure-function analysis. J. Virol. 68:1551-1563.[Abstract/Free Full Text]
    19. 19
  19. Hrabar, A., I. Vodopija, F. E. Andre, J. R. Mitchell, H. F. Maassab, A. V. Hennessy, and F. M. Davenport. 1977. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Dev. Biol. Stand. 39:53-60.[Medline]
    20. 20
  20. Jackson, D., A. Cadman, T. Zurcher, and W. S. Barclay. 2002. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J. Virol. 76:11744-11747.[Abstract/Free Full Text]
    21. 21
  21. Kobasa, D., M. E. Rodgers, K. Wells, and Y. Kawaoka. 1997. Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks. J. Virol. 71:6706-6713.[Abstract]
    22. 22
  22. Lear, J. D., Z. R. Wasserman, and W. F. DeGrado. 1988. Synthetic amphiphilic peptide models for protein ion channels. Science 240:1177-1181.[Abstract/Free Full Text]
    23. 23
  23. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96:9345-9350.[Abstract/Free Full Text]
    24. 24
  24. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.[CrossRef][Medline]
    25. 25
  25. Obrosova-Serova, N. P., A. N. Slepushkin, A. P. Kendal, M. W. Harmon, E. I. Burtseva, N. I. Bebesheva, A. L. Beljaev, N. I. Lonskaja, T. E. Medvedeva, A. Y. Egorov, et al. 1990. Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses. Vaccine 8:57-60.[CrossRef][Medline]
    26. 26
  26. Piller, S. C., G. D. Ewart, A. Premkumar, G. B. Cox, and P. W. Gage. 1996. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc. Natl. Acad. Sci. USA 93:111-115.[Abstract/Free Full Text]
    27. 27
  27. Pinto, L. H., L. J. Holsinger, and R. A. Lamb. 1992. Influenza A virus M2 protein has ion channel activity. Cell 69:517-528.[CrossRef][Medline]
    28. 28
  28. Plugge, B., S. Gazzarrini, M. Nelson, R. Cerana, J. L. Van Etten, C. Derst, D. DiFrancesco, A. Moroni, and G. Thiel. 2000. A potassium channel protein encoded by chlorella virus PBCV-1. Science 287:1641-1644.[Abstract/Free Full Text]
    29. 29
  29. Schubert, U., A. V. Ferrer-Montiel, M. Oblatt-Montal, P. Henklein, K. Strebel, and M. Montal. 1996. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1 infected cells. FEBS Lett. 398:12-18.[CrossRef][Medline]
    30. 30
  30. Shaw, M. W., P. W. Choppin, and R. A. Lamb. 1983. A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase. Proc. Natl. Acad. Sci. USA 80:4879-4883.[Abstract/Free Full Text]
    31. 31
  31. Shaw, M. W., and P. W. Choppin. 1984. Studies on the synthesis of the influenza B virus NB glycoprotein. Virology 139:178-184.[CrossRef][Medline]
    32. 32
  32. Steinhoff, M. C., N. A. Halsey, M. H. Wilson, B. A. Burns, R. K. Samorodin, L. F. Fries, B. R. Murphy, and M. L. Clements. 1990. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. J. Infect. Dis. 162:394-401.[Medline]
    33. 33
  33. Sugrue, R. J., G. Bahadur, M. C. Zambom, M. Hall-Smith, A. R. Douglas, and A. J. Hay. 1990. Specific structure alteration of the influenza haemagglutinin by amantadine. EMBO J. 9:3469-3476.[Medline]
    34. 34
  34. Sugrue, R. J., and A. J. Hay. 1991. Structural characteristics of the M2 protein of the influenza A viruses: evidence that it forms a tetrameric channel. Virology 180:617-624.[CrossRef][Medline]
    35. 35
  35. Sunstrom, N. A., L. S. Premkumar, A. Premkumar, G. Ewart, G. B. Cox, and P. W. Gage. 1996. Ion channels formed by NB, an influenza B virus protein. J. Membr. Biol. 150:127-132.[CrossRef][Medline]
    36. 36
  36. Takeda, M., A. Pekosz, K. Shuck, L. H. Pinto, and R. A. Lamb. 2002. Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J. Virol. 76:1391-1399.[Abstract/Free Full Text]
    37. 37
  37. Takeuchi, K., and R. A. Lamb. 1994. Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. J. Virol. 68:911-919.[Abstract/Free Full Text]
    38. 38
  38. Tomoda, T., H. Morita, T. Kurashige, and H. F. Maassab. 1995. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 13:185-190.[CrossRef][Medline]
    39. 39
  39. Tosteson, M. T., M. P. Caulfield, J. J. Levy, M. Rosenblatt, and D. C. Tosteson. 1988. The synthetic precursor specific region of pre-pro-parathyroid hormone forms ion channels in lipid bilayers. Biosci. Rep. 8:173-183.[CrossRef][Medline]
    40. 40
  40. Tosteson, M. T., D. S. Auld, and D. C. Tosteson. 1989. Voltage-gated channels formed in lipid bilayers by a positively charged segment of the Na-channel polypeptide. Proc. Natl. Acad. Sci. USA 86:707-710.[Abstract/Free Full Text]
    41. 41
  41. Watanabe, T., S. Watanabe, H. Ito, H. Kida, and Y. Kawaoka. 2001. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J. Virol. 75:5656-5662.[Abstract/Free Full Text]
    42. 42
  42. Williams, M. A., and R. A. Lamb. 1986. Determination of the orientation of an integral membrane protein and sites of glycosylation by oligonucleotide-directed mutagenesis: influenza B virus NB glycoprotein lacks a cleavable signal sequence and has an extracellular NH2-terminal region. Mol. Cell. Biol. 6:4317-4328.[Abstract/Free Full Text]
    43. 43
  43. Williams, M. A., and R. A. Lamb. 1988. Polylactosaminoglycan modification of a small integral membrane glycoprotein, influenza B virus NB. Mol. Cell. Biol. 8:1186-1196.[Abstract/Free Full Text]
    44. 44
  44. Wright, P. F., N. Okabe, K. T. McKee, Jr., H. F. Maassab, and D. T. Karzon. 1982. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J. Infect. Dis. 146:71-79.[Medline]

Journal of Virology, May 2003, p. 6050-6054, Vol. 77, No. 10
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.10.6050-6054.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hatta, M., Kohlmeier, C. K., Hatta, Y., Ozawa, M., Kawaoka, Y. (2009). Region Required for Protein Expression from the Stop-Start Pentanucleotide in the M Gene of Influenza B Virus. J. Virol. 83: 5939-5942 [Abstract] [Full Text]  
  • Muraki, Y., Murata, T., Takashita, E., Matsuzaki, Y., Sugawara, K., Hongo, S. (2007). A Mutation on Influenza C Virus M1 Protein Affects Virion Morphology by Altering the Membrane Affinity of the Protein. J. Virol. 81: 8766-8773 [Abstract] [Full Text]  
  • Betakova, T., Hay, A. J. (2007). Evidence that the CM2 protein of influenza C virus can modify the pH of the exocytic pathway of transfected cells. J. Gen. Virol. 88: 2291-2296 [Abstract] [Full Text]  
  • Bianchi, E., Liang, X., Ingallinella, P., Finotto, M., Chastain, M. A., Fan, J., Fu, T.-M., Song, H. C., Horton, M. S., Freed, D. C., Manger, W., Wen, E., Shi, L., Ionescu, R., Price, C., Wenger, M., Emini, E. A., Cortese, R., Ciliberto, G., Shiver, J. W., Pessi, A. (2005). Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor. J. Virol. 79: 7380-7388 [Abstract] [Full Text]  
  • Jackson, D., Barclay, W., Zurcher, T. (2005). Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55: 162-169 [Abstract] [Full Text]  
  • Muraki, Y., Washioka, H., Sugawara, K., Matsuzaki, Y., Takashita, E., Hongo, S. (2004). Identification of an amino acid residue on influenza C virus M1 protein responsible for formation of the cord-like structures of the virus. J. Gen. Virol. 85: 1885-1893 [Abstract] [Full Text]  
  • Hatta, M., Goto, H., Kawaoka, Y. (2004). Influenza B Virus Requires BM2 Protein for Replication. J. Virol. 78: 5576-5583 [Abstract] [Full Text]  
  • Dauber, B., Heins, G., Wolff, T. (2004). The Influenza B Virus Nonstructural NS1 Protein Is Essential for Efficient Viral Growth and Antagonizes Beta Interferon Induction. J. Virol. 78: 1865-1872 [Abstract] [Full Text]  
  • Sakai, A., Claire, M. St., Faulk, K., Govindarajan, S., Emerson, S. U., Purcell, R. H., Bukh, J. (2003). The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl. Acad. Sci. USA 100: 11646-11651 [Abstract] [Full Text]  
  • Horimoto, T., Takada, A., Iwatsuki-Horimoto, K., Hatta, M., Goto, H., Kawaoka, Y. (2003). Generation of Influenza A Viruses with Chimeric (Type A/B) Hemagglutinins. J. Virol. 77: 8031-8038 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hatta, M.
Right arrow Articles by Kawaoka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hatta, M.
Right arrow Articles by Kawaoka, Y.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»